While our platform holds broad therapeutic potential, we are strategically focused on obtaining first the regulatory approval for our system. To accelerate this path, we’ve selected the treatment of muscle atrophy as a lead program, because of its clinical relevance, ease of diagnosis, and rapid, quantifiable outcomes.
​
We are working to expand soon our pipeline to Type I Diabetes and in the next future to Age Associated Indications.​​
Muscle atrophy treatment (Lead program)
Here we aim to use our symbiotic particles to release an improved version of Follistatin into the host bloodstream. The therapeutic agent will act as a muscle stimulating factor and increase muscle mass in the host body. This project aims to dramatically improve the healthspan in old patients and astronauts. Moreover this project could help healthy people to increase their muscle mass in a safe way, replacing dangerous drugs like anabolic steroids.
​
​
​
Type I diabetes treatment (Secondary program)
Here we aim to use symbiotic particles to release an improved version of insulin into the host bloodstream and supply low Insulin amount to the host cells in patients of type I diabetes, replacing β-cells action. This project aims to save money and time to these patients, that will in this way stop to be "slave" of repeated external insulin injections.
Age-associated indication treatment (Platform future expansion)
This is the most ambitious of the three projects we commit to, here we aim to increase health parameters of old hosts by using symbiotic particles releasing a coktail of therapeutic agents into the host bloodstream. In particular, as a readout we will look at known validated biological clocks and multimorbidity measures to address an effect of our therapy in different host tissues of aged hosts, avoiding a lifespan study that will not be technically transposable to primates.
